Trial Profile
Phase 2 Trial of Lenalidomide (Revlimid)-Dexamethasone + Rituximab in Recurrent Small B-Cell Non-Hodgkin Lymphomas (NHL) Resistant to Rituximab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 28 Mar 2023 Status changed from active, no longer recruiting to completed.
- 03 Jun 2022 Planned End Date changed from 31 Dec 2024 to 31 Dec 2022.
- 17 Jun 2021 Results of a retrospective analysis to determine 5 and 10-yr outcomes presented at the 26th Congress of the European Haematology Association